Clinical

Dataset Information

0

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

ABSTRACT: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have metastatic colorectal cancer that has not responded to previous chemotherapy.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2005173 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Clinical Irinotecan and Capecitabine in Treating Patients With Solid Tumors
| 2003342 | ecrin-mdr-crc
Clinical Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
| 2002957 | ecrin-mdr-crc
Clinical Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
| 2004726 | ecrin-mdr-crc
Clinical Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
| 2004140 | ecrin-mdr-crc
Clinical Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma
| 2004126 | ecrin-mdr-crc
Clinical Chemotherapy in Treating Patients With Solid Tumors
| 2002684 | ecrin-mdr-crc
Clinical NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer
| 2007222 | ecrin-mdr-crc
Clinical Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
| 2003528 | ecrin-mdr-crc
Clinical Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
| 2004017 | ecrin-mdr-crc
Clinical Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
| 2004721 | ecrin-mdr-crc